Talactoferrin Alfa
drugOn this page
Also known as LF-00LF00TalactoferrinTalactoferrina alfaTalactoferrine alfaTalactoferrinum alfa
Summary
Talactoferrin Alfa (CHEMBL2108651) is a phase-3 clinical-stage unknown; indicated across 3 conditions including non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 3 conditions
- Clinical trials: 7
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108651 |
| Name | Talactoferrin Alfa |
| Type | Unknown |
| Max phase | 3 |
Also known as: LF-00, LF00, Talactoferrin, Talactoferrin alfa, Talactoferrina alfa, Talactoferrine alfa, Talactoferrinum alfa, TALACTOFERRIN ALFA
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 7.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 2 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00706862 | PHASE3 | UNKNOWN | Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer |
| NCT00707304 | PHASE3 | COMPLETED | Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer |
| NCT01273779 | PHASE2/PHASE3 | SUSPENDED | Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis |
| NCT00630656 | PHASE2 | COMPLETED | Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis |
| NCT00854633 | PHASE1/PHASE2 | UNKNOWN | Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants |
| NCT00923741 | PHASE1 | COMPLETED | Effect of Talactoferrin in Adults With Non-Small Cell Lung Cancer |
| NCT01528137 | PHASE1 | TERMINATED | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: non-small cell lung carcinoma